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Abstract
Background
Since recombinant human growth hormone (rhGH) became available in 1985, the spectrum
of indications has broadened and the number of treated patients increased. However, long-
term health-related quality of life (HRQoL) after childhood rhGH treatment has rarely been
documented. We assessed HRQoL and its determinants in young adults treated with rhGH
during childhood.
Methodology/Principal Findings
For this study, we retrospectively identified former rhGH patients in 11 centers of paediatric
endocrinology, including university hospitals and private practices. We sent a questionnaire
to all patients treated with rhGH for any diagnosis, who were older than 18 years, and who
resided in Switzerland at time of the survey. Three hundred participants (58% of 514 eligi-
ble) returned the questionnaire. Mean age was 23 years; 56% were women; 43% had iso-
lated growth hormone deficiency, or idiopathic short stature; 43% had associated diseases
or syndromes, and 14% had growth hormone deficiency after childhood cancer. Swiss sib-
lings of childhood cancer survivors and the German norm population served as comparison
groups. HRQoL was assessed using the Short Form-36. We found that the Physical Com-
ponent Summary of healthy patients with isolated growth hormone deficiency or idiopathic
short stature resembled that of the control group (53.8 vs. 54.9). Patients with associated
diseases or syndromes scored slightly lower (52.5), and former cancer patients scored low-
est (42.6). The Mental Component Summary was similar for all groups. Lower Physical
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Component Summary was associated with lower educational level (coeff. -1.9). Final height
was not associated with HRQoL.
Conclusions/Significance
In conclusion, HRQoL after treatment with rhGH in childhood depended mainly on the
underlying indication for rhGH treatment. Patients with isolated growth hormone deficiency/
idiopathic short stature or patients with associated diseases or syndromes had HRQoL
comparable to peers. Patients with growth hormone deficiency after childhood cancer were
at high risk for lower HRQoL. This reflects the general impaired health of this vulnerable
group, which needs long-term follow-up.
Introduction
When recombinant human growth hormone (rhGH) was introduced in 1985, it was only
approved for short children with growth hormone deficiency (GHD). Today, approved indica-
tions for rhGH treatment include GHD after cancer treatment, Turner syndrome, chronic
renal failure, Prader-Willi-Syndrome, born small for gestational age (SGA), short stature
homeobox deficiency, and, in some countries, idiopathic short stature (ISS). As the number of
indications has grown, so has the number of children treated with rhGH. Most frequently,
rhGH treatments are intended to promote growth, but rhGH therapy also improves body com-
position, cardiovascular outcomes, lipid profile, and bone density [1].
In adult patients, rhGH treatment improves health-related quality of life (HRQoL) [2, 3].
But it is not clear if treating patients with rhGH during childhood improves their long-term
HRQoL, because study results are contradictory [4]. Their results are hard to compare because
the studies are designed differently (time of assessment, use of different HRQoL instruments,
patient samples and control groups) [4]. Most research groups assessed HRQoL after patients
had initiated rhGH treatment, and few addressed long-term HRQoL after treatment [5–7]. Pre-
vious studies compared GHD patients with their siblings [6], norm populations [5], or them-
selves (longitudinally, at different time points) [8–10]. However, it is unclear which untreated
comparison group is appropriate. Many publications on HRQoL focused on single disorders,
like GHD, Turner syndrome, ISS, children born SGA or survivors of childhood cancer. Others
investigated heterogeneous cohorts that contained patients with different indications. It is
poorly known how widely HRQoL varies between patients with different underlying indica-
tions for rhGH treatment.
The current study aims to investigate this. We assessed HRQoL in young adults who had
been treated with rhGH during childhood, and to determine if the indication for rhGH treat-
ment, or other factors, influenced long-term HRQoL. We used the standardized questionnaire
Short Form 36 (SF-36) to collect data on HRQoL, and focused on long-term HRQoL in
patients whose linear growth was complete. We used both Swiss healthy untreated siblings of
childhood cancer survivors and the German norm population as comparison group.
Subjects and Methods
This study is based on data from the Swiss Growth Registry. It uses clinical data from original
medical charts and patient-reported answers to a postal questionnaire. The questionnaire was
sent in the framework of a large European study on “Safety and Appropriateness of Growth
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hormone treatments in Europe” (SAGhE) (http://cordis.europa.eu/result/rcn/57069_en.html).
This paper reports national data from Switzerland only.
Population and study design
For this cohort study, we retrospectively identified patients treated with rhGH since 1985 in 11
different Swiss centres of paediatric endocrinology. We included patients who were alive, born
before 31 March 1993 (aged18 years by the time of the study), and resident in Switzerland.
These patients had been treated with rhGH for the following indications: isolated GH Defi-
ciency (IGHD); Turner syndrome; cancer; multiple pituitary hormone deficiency (MPHD);
children born SGA; ISS; or, GHD associated with other defined diagnoses. We excluded
patients with unclear diagnoses or chronic renal failure.
In 2011, eligible participants received an information letter about the study and a question-
naire with a prepaid return envelope from their former paediatric endocrinology clinic. Non-
responders were mailed a reminder letter that included another copy of the questionnaire 4–6
weeks later. If they still did not reply, we reminded them by phone, or, if no phone number was
available, we sent them a third reminder letter.
Control group
We used two different comparison groups: Swiss healthy untreated controls and the German
norm population. We had recruited Swiss controls in a previous study, where we asked survi-
vors of childhood cancer for consent to contact their siblings [11–13]. In 2010 and 2011, these
siblings received a questionnaire that contained the SF-36. The questionnaire was comparable
to that sent to rhGH patients, but did not have questions about their history of rhGH treat-
ment. The siblings only received one reminder letter. We also used norm data from the Ger-
man Federal Health Survey, from which we selected a subgroup similar to our cohort in age
and sex distribution [14].
Ethics approval
We received ethics approval, through the Swiss Growth Registry, from the Swiss Federal Com-
mission of Experts for Professional Secrecy in Medical Research, and through non-obstat state-
ments from the ethics committees of the cantons of Bern and Zurich. In 2014, legislation on
research involving humans in Switzerland changed. We have renewed ethics approval at the
cantonal ethics commission of Bern.
Explanatory variables extracted from medical files
We extracted baseline demographic data and medical information on diagnosis and treatment
from original medical files kept by participating Swiss centres of paediatric endocrinology. The
data included age, sex, underlying indication for rhGH treatment, rhGH dose, age at start and
at end of rhGH treatment, height at start and at end of rhGH treatment, and final height (for
definition see end of paragraph). We classified diagnoses according to the European Society for
Paediatric Endocrinology system [15]. Patients who received rhGH after treatment of child-
hood cancer were classified according to the International Classification of Childhood Cancer
[16]. We stratified patients into three groups, based on their indication for rhGH treatment: 1)
Group I, healthy rhGH treated patients with IGHD and ISS; 2) Group II, patients with associ-
ated diseases or syndromes; and, 3) Group III, childhood cancer survivors (S1 Table). Where
data on rhGH dose was missing, we used the mean dose, between the previous and the next
visit, to impute it. If the dose for the next visit was also missing, we carried the last dose forward
Quality of Life after Growth Hormone Treatment in Childhood
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until a rhGH dose was again listed. If we could not determine age at start of rhGH treatment
from the medical files, we used age at the first indicated rhGH administration, which was rou-
tinely 6 weeks after treatment’s start. Missing age at the end of rhGH treatment was replaced
with the age at which patients achieved final height (marked by the end of a six-month period
during which patients grew 1 cm or less, or when they reached 18 (for women) or 20 (for men).
Explanatory variables from the questionnaire
We assessed the education level of participants from the questionnaire [11, 17]. Levels ranged
from primary, to secondary, to tertiary, as well as unknown.
Assessment of health-related quality of life
We assessed HRQoL using the Short Form-36 (SF-36) [18], a psychometrically validated
instrument that has been successfully applied in patients treated with rhGH in childhood [6,
19–22]. It consists of 36 questions that can be summarized into eight scales: physical function-
ing; role limitation due to physical health (role limitation physical); bodily pain; general health
perception; energy and vitality; social functioning; role limitation due to emotional problems
(role limitation emotional); and, mental health. The eight scales can be further aggregated into
a Physical Component Summary (PCS) and a Mental Component Summary (MCS) [18]. We
converted raw scores into T-scores (mean = 50, SD = 10, range 0–100) based on age- and sex-
stratified norm data from a public use-file of the German Federal Survey (N = 6964) [14].
Higher scores indicate better HRQoL.
Statistical Analyses
We compared rhGH patients who participated in the survey with these who did not, using chi
square tests for categorical variables, and t-tests for continuous variables. We also compared
rhGH treated participants to Swiss controls. We used appropriate weights to standardize on
age and sex to ensure that the marginal distribution in the stated variables of the Swiss controls
was identical to that in rhGH patients.
The means of the eight SF-36 scales and the two summary scores were used to compare the
HRQoL of rhGH patients and Swiss controls. We then stratified rhGH patients by indication
group and compared them to controls in a linear regression model.
In rhGH patients only, we performed univariable and multivariable linear regressions to
identify factors associated with physical and mental summary scores. In the multivariable
regressions, we included all variables that had been significantly associated with one of the two
outcomes (p0.05) in the univariable analysis. We assumed the a priori importance of sex,
therapy duration; rhGH dose received, height gain and final height, and included them in both
models, whether or not they were statistically significant. We used likelihood ratio tests to com-
pare models. Implementing several variables in a linear regression model does not interfere
with the precision of its estimates [23]. We performed all analyses using Stata 12.0 (StataCorp,
College Station, TX).
Results and Discussion
Characteristics of the Study Population
We contacted 514 eligible rhGH patients; 300 (58%) answered the SF-36 (Fig 1). Of the 1355
Swiss controls that we contacted, 695 (51%) answered the SF-36.
Fifty-six per cent of the participants were women; their average age was 23 years. Most par-
ticipants reached a secondary educational level (43%). The most common indication group for
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rhGH treatment was IGHD (37%), followed by Turner syndrome (16%), cancer (14%), MPHD
(13%), SGA (6%), ISS (6%), and other indications (8%). Most participants (61%) had received
an rhGH dose of between 30 and 50 μg/kg/day, and mean rhGH dose was 37 μg/kg/day. Mean
age at start of rhGH treatment was 10 years; mean age at the end of rhGH treatment was 16
years; mean rhGH treatment duration was 6 years; mean height gain was 1.2 standard devia-
tion score (SDS); and, mean final height was -1.0 SDS (Table 1).
Participants (n = 300) differed from non-participants (n = 214) by sex, indication, age at
therapy end, and therapy duration (Table 1). Both rhGH patients and Swiss controls had most
commonly attained a secondary educational level.
Health-related quality of life in rhGH patients and controls
When we compared the control groups (German norm population and Swiss controls) we
found that the German norm population had lower scores on all scales, except for role limita-
tion emotional.
Overall, the scores of patients treated with rhGH were significantly lower than those of
Swiss controls in the areas of physical functioning (mean of 48.7 vs. 53.1; p<0.001), role limita-
tion physical (49.3 vs. 50.9; p = 0.004), general health perception (52.8 vs. 56.5; p<0.001), and
the PCS (51.7 vs. 54.9; p<0.001; S2 Table). We found no differences in bodily pain, energy &
vitality, mental health, social functioning and role limitation emotional, and the MCS. Internal
consistency was excellent for bodily pain. It was good for physical functioning, role limitation
physical, energy and vitality, mental health, role limitation emotional and social functioning,
and was acceptable for general health perception (Cronbach’s alpha ranging from 0.76–0.91).
When we stratified the rhGH patients by indication group (Table 2 and Fig 2), we found
that mean scores of patients in Groups II and III were significantly different from those of
Swiss controls. Group II scored lower in the following scales: physical functioning (mean of
49.3 vs. 53.1); general health perception (52.8 vs. 56.5); and, the PCS (52.5 vs. 54.9). Patients in
Group III had the lowest scores in all scales. Their scores for physical functioning (36.0 vs.
53.1), role limitation physical (43.1 vs. 50.9), general health perception (46.7 vs. 56.5), social
functioning (44.3 vs. 50.8), and the PCS (42.6 vs. 54.9) were significantly lower.
Fig 1. Participants and response rate of the questionnaire survey. Fig 1 shows the flow diagram of our study population starting from those who were
contacted, and tapering to those included in the analysis. Patients were included if they received rhGH during childhood, were alive,18 years old at time of
survey, and resident in Switzerland. We excluded those with unclear diagnoses or chronic renal failure. Nine patients could not be contacted due to an
unknown address. Abbreviations: rhGH, recombinant human growth hormone; SCCSS, Swiss Childhood Cancer Survivor Study.
doi:10.1371/journal.pone.0140944.g001
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Table 1. Characteristics of the study population: comparison of non-participants, participants and Swiss controls.
rhGH treated non-
participantsa (n = 214)
rhGH treated
participants (n = 300)
Swiss controlsb
(n = 695)
n %c n %c p-valued n %c p-valuee
Sex <0.001 n.a.b
Male 131 61 131 44 306 44
Female 83 39 169 56 389 56
Current age (years) 0.396 n.a.b
<20 56 26 95 32 222 32
20–25 97 45 124 41 285 41
>25 61 29 81 27 188 27
Education n.a.f n.a.f <0.001
Primary 85 28 28 4
Secondary 129 43 297 43
Tertiary 61 20 245 35
Unknown 25 9 125 18
Indication for rhGH treatment <0.001 n.a.g n.a.g
IGHD 101 47 112 37
ISS 3 1 17 6
Turner 32 15 47 16
MPHD 32 15 40 13
SGA 14 7 18 6
Otherh 25 12 23 8
Cancer 7 4 43 14
Indication groupi <0.001 n.a.g n.a.g
Group I 104 49 129 43
Group II 103 48 128 43
Group III 7 3 43 14
rhGH dose (μg/kg/day) 0.310 n.a.g n.a.g
<30 45 23 75 27
30–50 119 61 170 61
>50 31 16 32 12
mean (SD) mean (SD) p-valuek mean (SD) p-valuek
Current age (years) 23.2 3.6 22.9 4.1 0.434 n.a.g n.a.g
rhGH dose (μg/kg/day) 39.0 10.8 37.2 11.1 0.073 n.a.g n.a.g
Age at start of treatment (years) 10.5 3.0 10.2 3.3 0.195 n.a.g n.a.g
Age at end of treatment (years) 15.8 2.4 16.5 2.7 0.010 n.a.g n.a.g
Treatment duration (years) 5.2 3.0 6.3 3.8 0.001 n.a.g n.a.g
Height gain (SDS) 1.1 0.8 1.2 1.1 0.312 n.a.g n.a.g
Final height (SDS) -0.2 0.9 -1.0 1.0 0.060 n.a.g n.a.g
NOTE: Percentages are based upon available data for each variable.
Abbreviations: GHD, growth hormone deﬁciency; IGHD, isolated growth hormone deﬁciency; ISS, idiopathic short stature; MPHD, multiple pituitary
hormone deﬁciency; n, number; n.a., not applicable/ not available; rhGH, recombinant human growth hormone; SD, standard deviation; SDS, standard
deviation score; SGA, small for gestational age
aNon-participants include 37 who were not included into mailing, 129 who did not respond and 85 who refused to participate.
bAge and sex standardized numbers and percentages are given for Swiss controls.
cColumn percentages are given.
dp-value calculated from chi-square statistics comparing rhGH patients participants vs. non participants.
ep-value calculated from chi-square statistics comparing rhGH patients participants vs. Swiss controls.
fInformation not available for non-responders.
gInformation on rhGH treatment is not applicable for Swiss controls.
hOther indications include calciopenic rickets, osteogenesis imperfecta, central diabetes insipidus, clinically deﬁned syndromes (except Turner syndrome),
skeletal dysplasia, insufﬁcient nutrient intake, disorders in organ systems, psychosocial growth failure, congenital adrenal hyperplasia.
iGroup I includes healthy patients with IGHD or ISS; Group II patients with associated diseases or syndromes; Group III childhood cancer survivors with
GHD.
kp- value calculated on two-sample mean-comparison test (t-test).
doi:10.1371/journal.pone.0140944.t001
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To investigate differences in mean scores for single disorders within Group I and II, we split
the rhGH patients by underlying indication (Table 3). The HRQoL of patients with IGHD,
Turner syndrome, and those born SGA was similar to that of Swiss controls, except in the cate-
gories of physical functioning (Turner, 51.0 vs. 53.1), bodily pain (Turner, 59.0 vs. 56.5), gen-
eral health perception (IGHD, 53.6 vs. 56.5), and the PCS (IGHD, 53.2 vs. 54.9). Persons with
ISS (N = 17) scored higher than Swiss controls in bodily pain (59.7 vs. controls, 56.6), role limi-
tation physical (53.3 vs. 50.9), general health perception (61.5 vs. 56.5), role limitation emo-
tional (52.6 vs. 48.7), and the PCS (57.4 vs. 54.9). In contrast, patients with MPHD (N = 40)
had lower scores than Swiss controls for physical functioning (48.2 vs. 53.1) and general health
perception (51.2 vs. 56.5). Patients with other disorders had lower physical functioning scores
(46.9 vs. 53.1) and PCS scores (50.2 vs. 54.9) than Swiss controls.
Factors associated with the Physical Component Summary (PCS)
In the univariable linear regression, a high educational level was associated with higher PCS.
But patients<20 years at time of study, patients from Group III, or patients who had received
an rhGH dose<30 μg/kg/day scored lower in the PCS. We found no association for sex, age at
Table 2. SF-36 mean T-scores and confidence intervals of rhGH treated patients, stratified by indication groups and compared to Swiss controls.
Group Ia Group IIa Group IIIa Swiss controls p-valueb
(n = 129) (n = 128) (n = 43) (n = 695)
Physical functioning Mean 52.3 49.3 36.0 53.1 <0.001
95% CI 51.3, 53.3 47.3, 51.3 31.0, 41.0 52.6, 53.6
Bodily pain Mean 55.8 56.8 53.3 56.5 0.119
95% CI 54.3, 57.2 55.4, 58.2 50.6, 56.1 55.8, 57.2
Role limitation physical Mean 50.9 49.8 43.1 50.9 <0.001
95% CI 50.0, 51.9 48.4, 51.2 40.1, 46.0 50.3, 51.5
Energy & vitality Mean 54.4 55.5 50.9 55.3 0.164
95% CI 51.8, 56.9 53.3, 57.6 47.2, 54.6 53.9, 56.6
Mental health Mean 52.6 52.8 51.0 54.2 0.184
95% CI 50.4, 54.8 50.8, 54.7 47.7, 54.2 53.1, 55.3
General health perception Mean 54.7 52.8 46.7 56.5 <0.001
95% CI 52.8, 56.6 50.8, 54.8 42.3, 51.0 55.5, 57.5
Role limitation emotional Mean 50.1 48.1 46.9 48.7 0.070
95% CI 48.9, 51.4 46.5, 49.7 44.2, 49.6 47.8, 49.6
Social functioning Mean 50.9 51.2 44.3 50.8 0.005
95% CI 49.3, 52.6 49.6, 52.8 40.8, 47.8 49.9, 51.6
PCS Mean 53.8 52.5 42.6 54.9 <0.001
95% CI 52.7, 54.9 51.0, 54.1 39.0, 46.2 54.3, 55.5
MCS Mean 51.4 51.6 51.3 51.3 0.997
95% CI 49.3, 53.6 49.6, 53.6 48.1, 54.5 50.1, 52.5
Higher T-scores indicate higher HRQoL (expected mean from German norm population = 50, SD = 10).
Abbreviations: 95% CI, 95% conﬁdence interval; GHD, growth hormone deﬁciency; IGHD, isolated growth hormone deﬁciency; ISS, idiopathic short
stature; MCS, mental component summary; n, number; PCS, physical component summary; rhGH, recombinant human growth hormone; SF-36, Short
Form-36.
aGroup I includes healthy patients with IGHD or ISS; Group II patients with associated diseases or syndromes; Group III childhood cancer survivors with
GHD.
bGlobal p-values were calculated from linear regression models, testing if the variable ‘indication group’ as a whole was associated with SF-36 mean T-
scores.
doi:10.1371/journal.pone.0140944.t002
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start or end of rhGH treatment, treatment duration, height gain, and final height (Table 4). In
the multivariable linear regression, reaching a tertiary education was associated with a higher
score in the PCS, while being in Group III was associated with a lower PCS. Sex, age, rhGH
dose, treatment duration, height gain, and final height were not significantly associated with
the PCS (Table 4).
Factors associated with the Mental Component Summary (MCS)
None of these factors was associated with the MCS in the univariable linear regression (S3
Table). In the multivariable linear regression, patients who were<20 years years at time of
study scored higher in the MCS. Sex, education, indication group, rhGH dose, treatment dura-
tion, height gain and final height were not significantly associated (S3 Table).
Fig 2. SF-36mean T-scores of rhGH-treated patients, stratified by indication groups and compared to Swiss controls. Fig 2 shows mean T-scores
for the eight SF-36 subscales and the two summary scores of rhGH treated patients, stratified by indication groups and compared to Swiss controls. Swiss
controls means were unadjusted. Higher T-scores indicate higher HRQoL (expected mean from German norm population = 50, SD = 10). P-values to
compare means between rhGH treated patients and Swiss controls were calculated using linear regression models.aGroup I includes healthy patients with
IGHD or ISS; bGroup II patients with associated diseases or syndromes; cGroup III childhood cancer survivors with GHD. Abbreviations: GHD, growth
hormone deficiency; IGHD, isolated growth hormone deficiency; ISS, idiopathic short stature; rhGH, recombinant human growth hormone; SF-36, Short
Form-36.
doi:10.1371/journal.pone.0140944.g002
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Discussion
This large, representative study found that HRQoL depended mainly on the underlying indica-
tion for rhGH treatment. In patients with IGHD or ISS, HRQoL was similar to Swiss controls.
In patients with associated diseases or syndromes, it was slightly lower, mostly in the physical
health scales: those treated with rhGH had a PCS of 52.5, while Swiss controls had a PCS of
54.9. Cancer patients had the lowest scores in all scales. Their results for four out of eight scales
(physical functioning, role limitation physical, general health perception and social
Table 3. SF-36 mean T-scores and confidence intervals of rhGH treated patients stratified by indications and compared with Swiss controls.
Group I Group II Group III Swiss
controls
IGHD
(n = 112)
ISS
(n = 17)
Turner
(n = 47)
MPHD
(n = 40)
SGA
(n = 18)
Othera
(n = 23)
Cancer
(n = 43)
(n = 695) p-
valueb
Physical
functioning
Mean 52.0 54.0 51.0 48.2 50.4 46.9 36.0 53.1 <0.001
95%
CI
50.9, 53.1 52.8, 55.1 49.2, 52.8 43.4, 53.0 46.9, 53.9 41.9, 52.0 31.0, 41.0 52.6, 53.6
Bodily pain Mean 55.2 59.7 59.0 55.8 58.0 53.2 53.3 56.5 <0.001
95%
CI
53.5, 56.8 57.2, 62.2 57.1, 61.0 53.2, 58.4 56.1, 59.9 49.3, 57.1 50.6, 56.1 55.8, 57.2
Role limitation
physical
Mean 50.6 53.3 49.7 49.5 49.9 50.2 43.1 50.9 <0.001
95%
CI
49.6, 51.6 51.8, 54.8 47.3, 52.1 47.0, 52.1 47.0, 52.9 47.0, 53.4 40.1, 46.0 50.3, 51.5
Energy & vitality Mean 53.3 61.3 56.2 53.8 55.8 56.6 50.9 55.3 0.163
95%
CI
50.6, 56.0 54.2, 68.4 53.1, 59.3 50.0, 57.5 49.5, 62.2 56.6, 62.6 47.2, 54.6 53.9, 56.6
Mental health Mean 52.1 55.7 53.2 51.1 55.0 53.0 51.0 54.2 0.266
95%
CI
49.8, 54.5 50.1, 61.3 50.5, 55.9 48.4, 53.8 48.7, 61.2 46.8, 59.2 47.7, 54.2 53.1, 55.3
General health
perception
Mean 53.6 61.5 53.5 51.2 54.5 52.4 46.7 56.5 <0.001
95%
CI
51.6, 55.6 57.3, 65.7 50.2, 56.8 47.2, 55.3 50.5, 58.5 48.0, 56.8 42.3, 51.0 55.5, 57.5
Role limitation
emotional
Mean 49.8 52.6 48.8 47.7 47.2 48.2 46.9 48.7 <0.001
95%
CI
48.4, 51.1 51.3, 53.9 46.4, 51.3 45.0, 50.4 42.6, 51.9 44.2, 52.2 44.2, 49.6 47.8, 49.6
Social functioning Mean 50.6 53.0 52.9 51.0 49.4 49.3 44.3 50.8 0.013
95%
CI
48.8, 52.4 49.1, 56.9 50.5, 55.3 48.6, 53.5 45.1, 53.7 44.6, 54.1 40.8, 47.8 49.9, 51.6
PCS Mean 53.2 57.4 53.8 52.1 53.4 50.2 42.6 54.9 <0.001
95%
CI
52.0, 54.4 55.5, 59.2 51.6, 55.9 48.5, 55.7 51.6, 55.2 46.7, 53.8 39.0, 46.2 54.3, 55.5
MCS Mean 50.9 54.9 52.3 50.2 51.5 52.3 51.3 51.3 0.872
95%
CI
48.6, 53.2 49.6, 60.2 49.5, 55.2 47.5, 52.9 45.5, 57.5 46.3, 58.4 48.1, 54.5 50.1, 52.5
Higher T-scores indicate higher HRQoL (expected mean from German norm population = 50, SD = 10).
Abbreviations: 95% CI, 95% conﬁdence interval; IGHD, isolated growth hormone deﬁciency; ISS, idiopathic short stature; MCS, mental component
summary; MPHD, multiple pituitary hormone deﬁciency; n, number; PCS, physical component summary; rhGH, recombinant human growth hormone; SF-
36, Short Form-36; SGA, small for gestational age.
aOther disorders include: clinically deﬁned syndromes (except Turner syndrome), skeletal dysplasia, disorders in organ systems, osteogenesis imperfecta,
central diabetes insipidus, congenital adrenal hyperplasia.
bGlobal p-values were calculated from linear regression models, testing if the variable ‘indication group’ as a whole was associated with SF-36 mean T-
scores
doi:10.1371/journal.pone.0140944.t003
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functioning) and the PCS were significantly lower than for Swiss controls. PCS was as low as
42.6. We found no association between final height and HRQoL.
Findings of other studies on health-related quality of life in young adults
with childhood onset rhGH treatment
When we compared the whole group of rhGH treated patients to Swiss controls, we found that
the HRQoL of patients was impaired mainly in the physical scales of the SF-36. Sandberg et al.
[6] and Lagrou et al. [5] had similar results.
When we looked at single indications only, we found similar results to Sandberg et al. for
healthy patients with IGHD [6]. These patients had a comparable HRQoL to Swiss controls in
all scales, except of a lower general health perception and PCS. Our findings for patients with
ISS, who had a similar or better HRQoL than Swiss controls, are comparable to those of a study
by Rekers-Mombark et al. [19], which found that the HRQoL of young adults with ISS treated
with rhGH was similar to the HRQoL of untreated adults with ISS, and to the normal
Table 4. Factors associated with the SF-36 Physical Component Summary in rhGH treated patients (n = 300).
Univariable regression Multivariable regression
coeff 95% CI p-valuea coeff 95% CI p-valuea
Sex 0.221 0.604
Male ref ref
Female -1.31 -3.41, 0.79 -0.58 -2.86, 1.70
Current age (years) 0.002 0.969
<20 -3.68 -6.09, -1.26 0.06 -2.75, 2.87
20–25 ref ref
>25 0.81 -1.73, 3.35 0.34 -2.49, 3.18
Education 0.001 0.018
Primary -0.63 -3.02, 1.76 -1.86 -4.71, 0.99
Secondary/Unknown ref ref
Tertiary 4.78 2.12, 7.42 2.84 0.002, 5.68
Indication groupb <0.001 <0.001
Group I ref ref
Group II -1.24 -3.30, 0.81 -0.10 -2.40, 2.20
Group III -11.17 -14.13, -8.21 -20.09 -26.59, -13.59
rhGH dose (μg/kg/day) <0.001 0.548
<30 -4.94 -7.43, -2.44 -1.60 -4.69, 1.50
30–50 ref ref
>50 -0.19 -3.62, 3.25 -0.78 -4.08, 2.53
Age at start of treatment 0.12 -0.19, 0.44 0.445 n.a. n.a. n.a.
Age at end of treatment -0.23 -0.61, 0.15 0.241 n.a. n.a. n.a.
Treatment duration -0.18 -0.46, 0.09 0.191 -0.06 -0.42, 0.29 0.719
Height gain 1.05 -0.02, 2.13 0.054 0.10 -1.35, 1.55 0.888
Final height 0.96 -0.16, 2.08 0.092 0.43 -0.91, 1.78 0.506
Abbreviations: 95% CI, 95% conﬁdence interval; GHD, growth hormone deﬁciency; IGHD, isolated growth hormone deﬁciency; ISS, idiopathic short
stature; n, number; n.a., not applicable / not available; ref, reference; rhGH, recombinant human growth hormone; SF-36, Short Form-36.
aGlobal p-values calculated with likelihood ratio test.
bGroup I includes healthy patients with IGHD or ISS; Group II patients with associated diseases or syndromes; Group III childhood cancer survivors with
GHD.
doi:10.1371/journal.pone.0140944.t004
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population. For women with Turner syndrome, we found that HRQoL was comparable to
Swiss controls, except for lower physical functioning and less bodily pain. Also, a French study
by Carel et al. found a normal HRQoL among Turner women [21], and a Canadian study
found no differences between treated and untreated Turner patients [20]. A Swedish study
reported that Turner women were more socially isolated, but in less pain than randomly
selected, age-matched women [24]. Dutch researchers reported that women with Turner syn-
drome had higher HRQoL than the general population in social functioning, role emotional
and bodily pain [22]. For patients with MPHD, HRQoL was lower than in Swiss controls for
physical functioning and general health perception. Other studies compared HRQoL between
MPHD and IGHD patients, with variable findings: some found lower HRQoL in MPHD
patients [5, 6]; others did not [25].
Discrepancies between our findings and those of other studies may have been caused by dif-
ferences in the populations under study, the comparison groups, or the instruments to assess
HRQoL in GH deficient children or adults [26]. This is a general problem for studies on long-
term outcomes of rhGH treatment, and can only be solved by conducting further cohort stud-
ies in a standardized way.
It was striking that survivors of childhood cancer (Group III) had the lowest HRQoL of all
rhGH treated patients and Swiss controls. Most (65%) of those patients had been diagnosed
with a CNS tumour (S1 Table). In a recent post-marketing study, adult patients with child-
hood-onset craniopharyngeoma had HRQoL similar to patients with childhood-onset extrasel-
lar tumours, or to patients with childhood-onset idiopathic congenital hypopituitarism [27].
But a previous analysis from the same database found that adult patients with craniopharyn-
geoma had lower HRQoL than the norm population [28]. Patients with central nervous system
tumours are likely to develop chronic health problems [29] that, in turn, may affect HRQoL.
Our group recently conducted a study of childhood cancer survivors and identified a range of
chronic health problems that negatively influenced HRQoL [12]. Endocrinopathies, neurologic
complications, or other late effects reported by those patients may decrease their HRQoL [30].
Limitations and strengths of the study
A limitation we share with most other studies on HRQoL in GHD is the lack of an untreated
control group of patients with the same diagnoses, since it is unethical to withhold necessary
treatment with rhGH from patients who require it. Sandberg et al. [6] compared patients to
their untreated siblings, but we did not have this option. Normal populations may also serve as
a comparison group, but may differ from the investigated population by year of assessment,
socio-demographic factors or cultural background [31]. Since Swiss norm data was not avail-
able, we used Germany norm data [14]. We also compared rhGH treated patients with Swiss
healthy untreated siblings of childhood cancer patients. However, all studies that use siblings of
sick patients as control groups suffer limitations, since those siblings, because they lived with
sick patients, may have lower HRQoL than their peers in the general population. On the other
hand, it is also possible that siblings reported a higher HRQoL, since they compared their own
HRQoL to that of their sick siblings [32].
Our response rate was only 58% (rhGH patients) and 51% (Swiss controls), despite sending
a postal reminder to both groups and reminding rhGH patients by phone. Non-participants
were similar to participants in their socio-demographic and treatment characteristics, but we
cannot rule out self-selection bias among both rhGH treated participants and the Swiss
controls.
Our study was strengthened by its inclusion of all types of patients treated with rhGH in
childhood. This enabled us to compare HRQoL among patients with different indications. We
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also included patients treated both in university hospitals and in private practice, so our dataset
represented the entire range of rhGH patients treated in Switzerland. While most other studies
on childhood rhGH treatment assessed short-term HRQoL during the patients’ growing
period, our study investigated long-term results after patients reached their adult height.
Interpretation of results and implication for practice
We identified patients with associated disorders and cancer survivors as subgroups at risk for
low HRQoL. Those patients may benefit from follow-up and psychological counselling. We
also found that the education of rhGH treated participants is a determinant of HRQoL, with
higher educated participants having a better quality of life. This association is well known and
reported previously [33]. We thought it remarkable that final height was not associated with
HRQoL, since HRQoL is generally believed to be lower in shorter persons [34]. We, however,
found no evidence that this assumption is true. A large longitudinal population-based cohort
study on the health of children and adolescents in Germany found that height had negligible
influence on HRQoL [35]. The same was demonstrated for adults in a nationwide population
study from France [36]. To determine whether GHD or the resulting short stature is responsi-
ble for reducing HRQoL, Stabler compared the incidence of social phobia in formerly treated
GHD patients, short non-treated sex- and age-matched adults, and the normal population
[37]. He found that GHD patients had a higher incidence of social phobia, and short non-
GHD people had a lower incidence of social phobia than the general population. Thus, reduced
HRQoL may be related to GHD indication, rather than to low final height.
Conclusion
We suggest that future research takes into account the influence of the underlying indication
when interpreting results, since our findings indicate that HRQoL after treatment with rhGH
in childhood is mainly determined by its underlying indication. HRQoL was normal in patients
with IGHD or ISS, slightly reduced in patients with associated diseases or syndromes, and
clearly lower in former childhood cancer patients than in Swiss controls.
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